QIAGEN NV (QGEN)
47.08
+0.26
(+0.56%)
USD |
NYSE |
Dec 04, 16:00
47.06
-0.02
(-0.03%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.21B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 8.14% |
| Valuation | |
| PE Ratio | 25.40 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.972 |
| Price to Book Value | 2.797 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.25 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5829 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 37.44% |
Profile
| QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. |
| URL | http://www.qiagen.com |
| Investor Relations URL | https://corporate.qiagen.com/investor-relations/overview |
| HQ State/Province | Limburg |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 04, 2026 (est.) |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 02, 2025 |
Ratings
Profile
| QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. |
| URL | http://www.qiagen.com |
| Investor Relations URL | https://corporate.qiagen.com/investor-relations/overview |
| HQ State/Province | Limburg |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 04, 2026 (est.) |
| Last Earnings Release | Nov. 04, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 02, 2025 |